^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

SEMA7A overexpression

i
Other names: SEMA7A, Semaphorin 7A (John Milton Hagen Blood Group), Sema Domain, Immunoglobulin Domain (Ig), And GPI Membrane Anchor, (Semaphorin) 7A (JMH Blood Group), Semaphorin 7A, GPI Membrane Anchor (John Milton Hagen Blood Group), John-Milton-Hargen Human Blood Group Ag, JMH Blood Group Antigen, Semaphorin-7A, Semaphorin-K1, Semaphorin-L, Sema K1, Sema L, CDw108, SEMAL, CD108, Sema Domain, Immunoglobulin Domain (Ig), And GPI Membrane Anchor, (Semaphorin) 7A, Sema Domain, Immunoglobulin Domain (Ig), And
Entrez ID:
Related biomarkers:
1year
Semaphorin 7A interacts with nuclear factor NF-kappa-B p105 via integrin β1 and mediates inflammation. (PubMed, Cell Commun Signal)
In conclusion, our findings suggest that the Sema7a (SEMA7A) mutation and high Sema7a (SEMA7A) expression both activate the NF-κB p50/p65 pathway via integrin β1 and play a crucial role in inflammatory responses. Video Abstract.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • SEMA7A (Semaphorin 7A) • IL1B (Interleukin 1, beta)
|
SEMA7A overexpression • SEMA7A expression
over2years
Semaphorin7a expression in breast cancers promotes susceptibility to immune checkpoint blockade (SABCS 2021)
Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer. Cancer research 78 , 6473-6485 (2018).
Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • SEMA7A (Semaphorin 7A)
|
PD-L1 expression • SEMA7A overexpression • SEMA7A expression
3years
[VIRTUAL] Semaphorin7A and estrogen work in concert to promote mammary tumor growth and alter the immune tumor microenvironment (AACR 2021)
Lastly, we treated Ctrl and SEMA7A OE tumors (in the presence of E2) with anti-PD1 or anti-PD-L1 therapies and only the SEMA7A OE tumors responded. These results indicate that E2 can induce SEMA7A expression in tumors and that SEMA7A can cooperate with E2 to inhibit anti-tumor immunity.
PD(L)-1 Biomarker • IO biomarker
|
SEMA7A (Semaphorin 7A)
|
PD-L1 expression • SEMA7A overexpression • SEMA7A expression